MedTrace Logo

Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression

NCT00770783 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-08-06

No results posted yet for this study

Summary

The investigators intend to test in a single center, clinical pilot efficacy study the primary hypothesis that Magnetic Seizure Therapy (MST) as add-on therapy to a controlled pharmacotherapy is efficacious in the treatment of refractory major depression assessed with the Hamilton Depression Rating Scale (HAMD).

Conditions

Interventions

DEVICE

Thymatron

Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks

DEVICE

Tonica MagPro MST

100% power, vertex placement, 3 times per week for 4 weeks

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Thomas E. Schlaepfer, MD · University Hospital, Bonn

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2013-09-30
Completion
2014-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00770783 on ClinicalTrials.gov